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Abstract 
Colorectal cancer is one of the commonest cancers in the world and it is also a common cause of cancer-related 
death worldwide. Despite advanced treatment strategies, the disease is rarely cured completely due to recurrence. 
Evidence shows that this is due to a small population of cells, called cancer stem cells (CSCs), in the tumour mass 
that have the self-renewal and differentiation potential to give rise to a new tumour population. Many pre-clinical 
and clinical studies have used curcumin and its analogues as anti-cancer agents in various types of cancer, including 
colorectal cancer. Intriguingly, curcumin and its analogues have also recently been shown to be effective in lowering 
tumour recurrence by targeting the CSC population, hence inhibiting tumour growth. In this review, we highlight 
the efficacy of curcumin and its analogues in targeting colorectal CSC and also the underlying molecular mechanism 
involved. Curcumin, in the presence or absence of other anti-cancer agents, has been shown to reduce the size of 
tumour mass and growth in both in vivo and in vitro studies by affecting many intracellular events that are associated 
with cancer progression and CSC formation. An insight into the molecular mechanism has unraveled the mode of 
action via which curcumin could affect the key regulators in CSC, importantly; (1) the signaling pathways, including 
Wnt/β-catenin, Sonic Hedgehog, Notch and PI3K/Akt/mTOR, (2) microRNA and (3) the epithelial-mesenchymal transi-
tion at multiple levels. Therefore, curcumin could play a role as chemosensitiser whereby the colorectal CSCs are now 
sensitised towards the anti-cancer therapy, therefore, combination therapy using anti-cancer agent with curcumin 
could be much more effective than treatment using a single cancer agent. This potential treatment modality can 
be further developed by employing an effective delivery system using a nanotechnology based approach to treat 
colorectal cancer.
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Overview of colorectal cancer stem cells 
and curcumin
Colorectal cancer is the third most common cancer, 
affecting men and women equally [1], and it is the second 
commonest cause of cancer-related death in the United 
States and many other developed countries [2, 3]. For 
patients with advanced colon cancer, the 5-year survival 
rate is as low as 8 %. It is interesting that, despite the use 
of aggressive surgical tumour resection and chemother-
apy, nearly 50  % of patients with colorectal carcinoma 
experience a recurrence [4]. Increasing evidence sug-
gests that colorectal cancer cells are driven by a subset of 
self-renewing cells, termed cancer stem cells (CSCs) or 
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tumour initiating cells, which are distinct from the bulk 
of the tumour cells [5, 6].
CSC can be defined as cells in a tumour with tumour 
initiating potential. They can be derived from either self-
renewing normal stem cells or from progenitor cells that 
have acquired the ability of self-renewal due to muta-
tion or the dedifferentiation of mature neoplastic cells 
[7]. Although they are small in number in a cancer cell 
mass, with self-renewal and differentiating properties 
like normal stem cells, they are resistant to eradication 
by chemotherapy. Hence, targeting these cell populations 
becomes crucial in the treatment of cancer.
Curcumin, a bioactive compound in the famous Indian 
spice turmeric, obtained from the plant Curcuma longa, 
is well known for its anti-inflammatory, antioxidant, and 
antimicrobial activities [8–10]. Besides, curcumin has 
been shown to have anti-cancer properties [9–12], and its 
inhibitory effects on various mechanisms have been dem-
onstrated in various human cancer cell lines. Curcumin 
induces cell death through a variety of mechanisms by 
targeting pathways, transcription factors, membrane 
receptors, kinases and cytokines [13].
As currently available conventional treatment modali-
ties for colorectal cancer, which include surgery, radia-
tion, and chemotherapy, are still not effective in curing 
the disease due to the incidence of secondary cancer or 
tumour, curcumin and its analogues could provide an 
effective treatment either as a stand alone or in combi-
nation with other chemotherapy drugs. However, there 
is a need to evaluate the effectiveness of the therapeutic 
action and its underlying mechanism in order to develop 
an effective treatment to cure cancer.
Colorectal cancer
The incidence and rate of mortality associated with colo-
rectal cancer increases with age. The incidence rate of 
colorectal cancer is known to be 15 times higher in adults 
aged 50 years and above than in those who are between 
20 and 49 years of age [14]. Colorectal cancer incidence 
and mortality rates are highest in Afro-American popu-
lations; incidence rates and mortality rates are, respec-
tively, about 20 and 45  % higher than those in white 
populations [15]. There is a strong correlation between 
genetic predisposition and colorectal cancer occurrence. 
People with a first-degree relative who has had colorectal 
cancer have two to three times the risk of developing the 
disease compared to individuals with no family history. 
If the relative was diagnosed at a young age or if there 
is more than one affected relative, the risk increases to 
three to six times that of the general population [16, 17]. 
About 20 % of all colorectal cancer patients have a close 
relative who has been diagnosed with the disease [18].
About 5  % of patients with colorectal cancer have 
a well-defined genetic syndrome that causes the dis-
ease [19]. Two genetic syndromes are strongly linked to 
colorectal cancer; the most common is hereditary non-
polyposis colon cancer (HNPCC), also known as lynch 
syndrome, and familial adenomatous polyposis (FAP) 
syndrome. HNPCC accounts for 2–4  % of all colorectal 
cancers, and FAP accounts for 1 % of all colorectal can-
cers [19]. Patients with chronic inflammatory bowel syn-
drome (IBS), particularly ulcerative colitis and Crohn’s 
disease, have an increased risk of developing colorectal 
cancer [20]. Other risk factors include type 2 diabetes, 
being overweight or obese, physical inactivity, smoking 
and drinking alcohol. Consumption of a diet high in red 
meat or processed meat can increase the risk of colorec-
tal cancer. Diets low in vegetables, fruits and whole grains 
have also been linked with an increased risk of develop-
ing colorectal cancer [21, 22].
Early detection is important in preventing colorectal 
cancer. People who have a strong family history of colo-
rectal cancer polyps or cancer are advised to do genetic 
screening for HNPCC-associated gene mutation and 
FAP-associated gene mutation. Colonoscopy, flexible 
sigmoidoscopy, double-contrast barium enema, CT colo-
noscopy are performed every 5 years to detect the pres-
ence of colorectal polyps and cancer. Non-invasive tests 
such as fecal occult blood test (FOBT) can be done annu-
ally for the detection of colorectal cancer [23]. Depend-
ing on the stage and site of the tumour, treatment options 
can vary. Tumour resection surgery may be combined 
with radiation or chemotherapy as either adjuvant or 
neo-adjuvant therapy. 5-fluorouracil and Oxaliplatin are 
the most commonly used drugs among the many more 
combinations that can be used for treating colorectal 
cancer.
Despite advances in screening and surgical treatment, 
metastatic cancer has no known cure, and the 5-year 
survival rate is disappointingly low (approximately 8 %). 
Such alarming ineffectiveness of standard anti-cancer 
therapies has been attributed to the existence of relatively 
rare, highly drug-resistant, quiescent or slow proliferat-
ing cells with stem-like properties called CSCs [24, 25].
Colorectal cancer stem cells
Although only a small subpopulation (<1  %) of over-
all cancer cells have the ability to proliferate extensively 
and form new tumours [26, 27], they are the crucial 
component responsible for tumour recurrence, therapy 
resistance and metastasis [28, 29]. CSCs may undergo 
symmetrical cell division into two identical daughter 
CSCs or asymmetrical cell division to give rise to one 
daughter CSC and one differentiated progenitor cell, 
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resulting in a numbered expansion of CSCs as the tumour 
grows [30]. It has been recently suggested that CSCs may 
arise from normal stem cells, progenitor cells, or more 
differentiated cells [30, 31] through multiple mutations of 
genes as a result of genomic instability [32] or oncogene-
induced plasticity [33].
CSCs are not synonymous with normal stem cells. 
They differ significantly from normal stem cells in their 
tumourigenicity; CSCs can form tumours when trans-
planted into animals, but normal stem cells cannot [30]. 
Thus, CSCs are defined by four key characteristics: (a) 
self-renewal—CSC populations can be serially trans-
planted through multiple generations, indicating they 
have self-renewing capacity; (b) differentiation—pluri-
potent cells can not only undergo symmetrical cell divi-
sion to form tumourigenic daughter CSCs but can also 
generate bulk populations of non-tumourigenic cells by 
asymmetric cell division; (c) tumourigenicity—a small 
subpopulation of CSCs have tumourigenic potential 
when transplanted into animals and (d) specific surface 
markers, by which the CSC subpopulation can be sepa-
rated from non-stem cells [28, 34, 35].
CSCs can be isolated in vitro by the expression of spe-
cific cell surface markers, signaling pathways, intracel-
lular enzyme activities and sphere forming ability in a 
non-adherent medium [36, 7, 37, 38]. Common cell sur-
face markers for colorectal CSCs include CD133, CD44, 
CD166, CD24, CD29, as well as Hoechst dye efflux or 
aldehyde dehydrogenase activity (ALDH), all of which 
characterize tumourigenicity and metastatic acquaint-
ance, particularly through their ability to repopulate into 
colonies from a single cell [39, 40]. Additional assays are 
used to support the functional properties of CSCs char-
acterized by their ability to show invasiveness, stemness 
properties and drug-resistance in in  vitro assays. These 
include the 3-dimensional tumoursphere forming assay, 
invasion assay using Matrigel as well as the drug resist-
ance assay for various chemo-/radio therapy agents 
[41–44]. However, in vitro assays alone are not enough to 
demonstrate the detection of CSCs, and in vivo assays are 
regarded as the gold standard, including serial transplan-
tation in animal models [30]. This is the process in which 
tumour cells are transplanted into immunocompromised 
(typically NOD/SCID) mice, and tumour growth is moni-
tored; then, xenograft tumours or primary tumours are 
isolated from the mice and implanted again into other 
immunocompromised mice to demonstrate self-renewal 
and tumour formation capacities [30, 45, 46].
Curcumin: properties and its derivatives
Curcumin is a well-known dietary polyphenol derived 
from the rhizomes of turmeric (Curcuma longa), an 
Indian spice which is usually used in the preparation of 
mustard and curry [8, 47]. Curcumin is well-known for 
its anti-inflammatory, antioxidant, and antimicrobial 
activities [8, 10, 48], and it has been widely studied as a 
cancer chemopreventive agent in a wide range of can-
cer models, including head and neck, melanoma, brain, 
breast, colon, pancreatic, prostate and ovarian cancers, 
over the past three decades [48–50].
There are three curcuminoids, namely curcumin, dem-
ethoxycurcumin and bisdemethoxycurcumin, which are 
obtained from the natural extract of Curcuma longa, of 
which curcumin is the principal constituent [51]. Novel 
analogues of curcumin are also used as they dramatically 
improve the stability, bioavailability, and growth-inhibi-
tory capacity, compared to curcumin, which has limited 
use in clinical applications due to its poor bioavailability 
[52, 53]. Furthermore, various nanotechnology-based 
formulations of curcumin have recently been considered 
for an innovative approach to overcoming the bioavail-
ability and stability issues in brain tumour [54] and colo-
rectal cancer [55].
Effects of bioactive curcumin on cancer stem cells
During the past few years, a number of studies have sug-
gested that curcumin has the potential to target CSCs 
through direct or indirect influences on the CSC self-
renewal pathways [56–59]. Three major signaling path-
ways in which curcumin plays a pivotal role in CSC 
self-renewal behavior are the Wnt/β-catenin, Sonic 
Hedgehog (SHH), and Notch pathways [29]. A consider-
able number of in  vitro and preclinical studies strongly 
support the potential use of curcumin as a cancer 
chemo-preventive agent. Therefore, numerous studies 
have been conducted to address the pharmacokinetics, 
safety and efficacy of curcumin in different types of can-
cer in human subjects. Published studies have generally 
reported no toxicity with a moderate dose of curcumin 
over a few months, and a number of studies have shown 
the beneficial effects of curcumin against a variety of pre-
malignant or malignant disorders [60–66].
The mechanisms of CSC resistance to chemo- and radi-
ation therapies and the potential targets for CSC-focused 
drug development have been extensively studied. It has 
been convincingly demonstrated that, in many cancers, 
the tumourigenic cells expressing common CSC markers, 
particularly CD133 and CD44, are not only resistant to 
commonly used anti-cancer drugs in colorectal cancer, 
including 5-FU and Oxaliplatin, but their number is also 
significantly increased after treatment [67–77]. Recently, 
much attention has been focused on several phytochemi-
cals showing promising anti-cancer abilities/properties 
and specific CSC-targeted activities to help overcome 
the resistance and recurrence found with traditional 
therapies. Since CSCs are more resistant to conventional 
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therapies in comparison with the differentiated cells con-
stituting the tumour bulk, a combination of curcumin 
and conventional anti-cancer drug therapies may have 
the potential to overcome tumour resistance and reduce 
recurrence.
The efficacy of curcumin in targeting colorectal CSCs, 
which is summarised in Table  1, will be discussed in 
this section. Seven studies were selected for the review, 
two of which included an in vivo study in mice (S1 and 
S2). These two studies were conducted both in vitro and 
in  vivo. In S1 by Lin et  al., a new curcumin analogue, 
GO-Y030, was used to target colorectal CSCs [78]. Per-
sistent activation of the STAT signal was seen in most of 
the cancers, including colorectal cancer, and GO-Y030 
inhibited the phosphorylation of STAT3. Therefore, there 
was decrease in tumour formation and growth achieved 
via induction of apoptosis. The study was also conducted 
in  vivo and there was a reduction in tumour growth, 
weight and mass by the same mechanism of STAT3 inhi-
bition. Thus, it can be concluded that GO-Y030 is effec-
tive both in  vitro and in  vivo. In S2 by Wang et  al, the 
encapsulated curcumin (CSO-SA micelles) was com-
pared with free curcumin and empty CSO-SA [79]. Cur-
cumin-loaded CSO-SA micelles were designed to achieve 
better stability and efficiency. They inhibited the CSC 
population by reducing the expression of CD44+/CD24+ 
markers and suppressed spheroid formation both in vitro 
and in vivo. Hence, the new formulation of curcumin can 
be more beneficial for bioavailability.
Difluorinated-curcumin (CDF) was used to treat 
chemo-resistant colorectal cancer cells (FOLFOX-resist-
ant cells) in S3 by Kanwar et  al. [42]. The conventional 
chemotherapy used for colorectal cancer is 5-fluorouracil 
and Oxaliplatin (5-FU and Ox), the combination is called 
FOLFOX. There were chemo-resistant cell populations, 
called CSCs, and they were treated with a combination 
of CDF and FOLFOX. The results showed significant 
inhibition of CSCs with a combination of CDF and FOL-
FOX compared to curcumin with FOLFOX. Similarly, the 
study of the effect of CDF on the expression of miR-21 
and PTEN, in which the inverse relationship of expres-
sion was shown to be associated with tumourigenicity in 
cancers such as pancreatic cancer, was taken further by 
Roy et al. in S7 [82, 83]. Treatment with CDF was shown 
to down-regulate miR-21, up-regulate PTEN expression, 
and subsequently inactivate the Akt pathway, marked 
by a reduction of pAkt in the colonosphere. The effect 
of curcumin treated cells on the cancer colony was not 
shown. The above three studies show that novel formu-
lations of curcumin are more effective than natural cur-
cumin in inhibiting colorectal CSCs due to their superior 
stability, better accumulation and enhanced therapeutic 
efficacy in vivo.
In S4, by Nautiyal et al. curcumin was combined with 
Dasatinib for the treatment of chemo-resistant colorec-
tal cancer cells [43]. This combination treatment reduced 
tumour growth, colonosphere formation and extracel-
lular invasion of the colorectal cancer cells. CSC mark-
ers: ALDH1, CD133, CD44 and CD 166 expression were 
found to be reduced by up to 80–90  %. Moreover, cur-
cumin was shown to reduce the toxicity of Dasatinib, as 
it lessened the dosage of the latter required to kill the 
cancer cells. This study indicated that combination ther-
apy is highly effective in inhibiting carcinogenesis, and 
that the incorporation of curcumin has a greater benefit 
with reduced drug toxicities. In S5 by Yu et al. curcumin 
was combined with FOLFOX to treat FOLFOX-resistant 
colorectal cancer cells [44]. The combined treatment 
markedly reduced the expression levels of CD166, CD44 
and EGFR in FOLFOX-surviving cells. It also caused dis-
integration of colonospheres, and the combination ther-
apy was shown to be more effective than conventional 
chemotherapy alone.
An important aspect of carcinogenesis involves the 
dynamic interactions between the cancer cells and their 
microenvironment. More recently, S6, Buhrmann et  al., 
showed the role of the tumour microenvironment in 
tumour progression via the interaction of colorectal 
cancer cells in the stromal fibroblast, and the effect of 
curcumin treatment on these interactions [80]. The mon-
olayer and high-density co-culture method was utilised to 
mimic the in vivo micro-environment of colorectal cancer 
cells in the stromal fibroblast. It was demonstrated that 
the cross-talk between the co-cultured cells synergisti-
cally promoted tumour activity, reflected by the activa-
tion of tumour-promoting factors, as well as metastatic 
activity, compared to the control monolayer cultures. This 
activity was significantly increased with 5-FU treatments, 
demonstrating the enrichment of CSC populations. How-
ever, curcumin was shown to dramatically inhibit these 
activities and sensitize them to 5-FU treatments.
In the light of the seven studies discussed, curcumin 
and its analogues target colorectal CSCs by multiple 
modulations at the molecular and cellular level, summa-
rised in Fig.  1. Briefly, chemo-resistant colorectal CSC, 
either in  vitro or in  vivo, is effectively suppressed with 
curcumin treatment, either alone or in combination, by 
the complex mechanism of targeting intracellular targets 
such as epigenetic modification, miRNA regulation, as 
well cellular processes such as cell death, CSC-stromal 
cell interactions, and EMT in the CSC, thus effectively 
affecting the growth of the tumour cells. Taken together, 
curcumin effectively increases the sensitivity of the CSC 
either alone or when acting synergistically with chemo-
therapy drugs, thus overcoming CSC-associated drug 
resistance.
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In a nutshell, curcumin, a naturally-occurring phyto-
chemical, and its analogues were found to be effective in 
targeting chemo-resistant colorectal cancer cells. Modi-
fied formulations of curcumin were also synthesized to 
achieve better stability. Curcumin has been investigated 
in relation to many cancers and has proven to be a safe 
adjuvant or neo-adjuvant anti-cancer treatment. Here, 
it was studied in relation to the targeting of a small 
population of resident cells that are responsible for can-
cer recurrence in spite of the many advances in cancer 
treatment. These cells, known as CSCs play a major role 
in developing treatment resistance and tumour recur-
rence. Curcumin and its analogues significantly sup-
press CSCs both in vitro and in vivo, which can be seen 
by the reduced expression of CSC markers for colo-
rectal cancer such as ALDH1, CD24, CD133, CD44, 
and CD166. Moreover, curcumin can be combined 
with conventional anti-cancer chemotherapies, such as 
5-fluorouracil, Oxaliplatin and Dasatinib, to make the 
treatment more effective. With curcumin, the dose of 
chemotherapy can be lowered and, thus, drug toxicity is 
also reduced.
Mechanism of action of curcumin on cancer cells 
and cancer stem cells
Cancer stem cell related signaling pathways
In stem cells, normal proliferation, differentiation and 
cell renewal are controlled by a number of signaling 
pathways. Several studies have identified the key sign-
aling pathways that play crucial roles in the growth and 
survival of stem cells from both normal and cancer tis-
sue, such as Wnt/β-catenin, Notch, SHH and BMP sign-
aling [36, 7]. Accumulating evidence has also shown the 
contribution of the PI3K/Akt pathway, implicated in the 
aggressiveness of CSC phenotypes [74, 84, 85]. In nor-
mal stem cells, self-renewal pathways play major roles 
in promoting proliferation and defining cell fate [29]. A 
large body of evidence has shown that the aberrant acti-
vation of these key regulatory pathways in cancer tissue, 
on the other hand, contributes towards the formation of 
CSCs and, therefore, leads to chemo-resistance, which 
causes the recurrence of tumour after chemotherapy 
treatment. Importantly, several studies have suggested 
cancer cells acquire stemness and drug resistance prop-
erties by the activation of the Wnt/β-catenin, Notch and 
Fig. 1 Effect of curcumin and curcumin analogue on colorectal cancer stem cells. Curcumin acts as an anti-tumour compound which targets the 
various factors or pathways that are implicated in colorectal cancer at many levels. Single or combined treatment of colorectal CSC has been shown 
to effectively inhibit tumour growth and, consequently, an improved sensitivity towards chemotherapy can be achieved. Key: down arrow down-
regulate/decreased expression, up arrow up-regulate/increased expression, perpendicular symbol inhibit
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SHH pathways [86]. Whether epithelial-mesenchymal 
transition (EMT), a key event implicated in the forma-
tion of CSC, is regulated via activation of the CSC related 
signaling pathways or induced by the tumour fibroblasts 
micro-niche remains to be elucidated.
Even so, theoretically, the CSC related pathways might 
be potential targets for cancer therapy, but in practice it 
is not an easy task due to the complex nature of signaling 
transduction and the involvement of curcumin effectively 
inhibiting activation of these pathways at the receptor 
level via multiple modes of action: inhibition of the ligand 
binding site of the receptor, inhibition of the formation 
of the receptor complex, and/or reduction in the abun-
dance of the receptor [87–89], which is evidenced in all 
of these signaling pathways. Curcumin also effectively 
reduces the expression levels of the downstream effectors 
of these pathways at the mRNA and protein levels. This is 
evidenced by the reduction in the stability of β-catenin, 
the downstream mediator of Wnt/β-catenin signaling 
[90, 91], the reduction in Gli1 mRNA levels, which affects 
SHH signaling, [92] as well as inhibition of the phospho-
rylation of the downstream kinases signal transducers in 
the PI3K/Akt/mTOR signaling pathways [87, 93, 94]. At 
the transcriptional level, curcumin has been reported to 
reduce the components of the transcriptional complex, 
such as p300, that reduces the expression of the target 
genes [95, 96] and inhibits Gli1 transcriptional activity 
in the Shh pathway [97, 98]. The effect of curcumin and 
its analogues on CSCs and the self-renewing signaling 
pathways studied using both in vitro and in vivo experi-
ments in various cancer types indicates the potency of 
this compound in enhancing the efficacy of the current 
cancer treatment modality, chemotherapy. This is par-
ticularly important owing to the effectiveness of these 
compounds in targeting CSCs at multiple levels of the 
signal cascade, which confers the survival, stemness and 
invasion properties of these cells and ensures the delivery 
of a more effective anti-cancer action by curcumin and 
its analogues. The mechanism by which curcumin and 
its analogues might be utilized in anti-cancer therapy, via 
the modulation of the signaling pathway, is illustrated in 
Fig. 2 and described in Table 2.
Regulation of microRNAs
MicroRNAs (miRNAs) are a class of short highly con-
served non-coding RNAs which have emerged as key 
post-transcriptional regulators of gene expression [100]. 
Numerous data have revealed that miRNA regulates a 
variety of biological events, including development, cell 
proliferation, differentiation, senescence and apoptosis 
[100–102].
Only a few reports have so far investigated the effect of 
curcumin on miRNA expression. It was first found that 
miR-22 was the most up-regulated while miR-199a* the 
most suppressed in a human pancreatic carcinoma cell 
line treated with curcumin. The two downstream targets 
of miR-22, SP1 transcription factor (SP1) and oestrogen 
receptor 1 (ESR1), are implicated in promoting tumour 
development [103]. While the overexpression of SP1 pro-
tein contributes to metastasis in diverse tumour types, 
its inhibition in colorectal CSC has been shown to mark-
edly suppress CSC growth and induce apoptosis, which 
Fig. 2 Mechanism of action of curcumin on cancer cells and cancer stem cells by targeting the self-renewal signalling pathways. Curcumin modu-
lates the fate of cancer stem cell by targeting misregulated signalling pathways at multiple cellular levels namely; receptors, downstream effectors 
and transcriptional activity in a Hedgehog, b Notch, c PI3K/Akt/mTOR and d Wnt/β-catenin signalling pathways
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can be achieved by treating the cells with curcumin. 
[104]. In another study, with a longer treatment period 
of 2 days, curcumin was found to promote human ade-
nocarcinoma cell apoptosis through modulation of miR-
186* and targeting its down-stream caspase-10 pathway 
[102]. Some miRNAs enhance the sensitivity of cancer 
cells to anti-cancer drugs and modulate their functional-
ity via CD expression, such as miR-21 [105]. In human 
colorectal cancer RKO and HCT116 cells, curcumin 
inhibits the transcriptional regulation of miR-21 via 
AP-1, suppresses cancer cell proliferation, invasion and 
metastasis, and stabilises the expression of the tumour 
suppressor programmed cell death protein 4 (Pdcd4) 
[41]. Likewise, miR-200, which is up-regulated in cells 
treated with curcumin, enhances the sensitivity of can-
cer cells to anti-cancer drugs in addition to playing a key 
role in reversing EMT [106]. Furthermore, miRNAs have 
been reported to modulate tumour-suppressive mRNA. 
Some miRNAs have been identified that mask cancer 
cells from apoptosis, which is extremely important. Up-
regulation of tumour-suppressive miRNAs, such as Let-
7, miR-26a, miR-101 and miR-146, has been detected in 
cancer cells treated with curcumin [105, 106]. The role of 
curcumin as an anti-cancer therapy via the regulation of 
miRNA expression is depicted in Fig. 3.
Epithelial‑mesenchymal transition
Epithelial-mesenchymal transition (EMT) is a complex, 
highly regulated process during embryonic development 
in which certain epithelial cells undergo morphogenetic 
changes to become cells with mesenchymal cell-like prop-
erties. This process allows recruitment of the mesenchy-
mal cells to migrate to a specific site in the developing 
embryo and consequently differentiate to form epithelial 
cells at a distal location via the reverse process, mesen-
chymal-epithelial transition (MET) [107]. The metastasis 
process during tumourigenesis progression has been asso-
ciated with the initiation of the EMT process, where can-
cer cells acquire aggressive and invasive properties. The 
signaling pathways involved in developmental EMT have 
also been implicated in the self-renewal and maintenance 
of CSCs, suggesting that EMT has a role in the malignant 
progress of tumour cells caused by CSCs [108, 109].
The TGF-β pathway plays a crucial role in the regula-
tion of transcriptional repressor genes during the initia-
tion of EMT, such as Zeb1, Snail, Slug and Twist [108]. 
These transcription factors repress the expression of 
E-cadherin, activating cascades of the cellular events 
and genes driving the EMT [110]. The miRNA family is 
also an important regulator of the EMT process, particu-
larly the miR-200 and the let-7 family, thus it may also 
Table 2 Curcumin targets multiple levels of the cancer stem cell related signaling pathways
Cancer stem cell 
related signaling 
pathways
Curcumin targets multiple levels of signal transduction pathways References
Hedgehog signaling Receptor: Curcumin treatment led to a decrease in Shh and PTCH1 at protein level, triggering apoptosis in 
medulloblastoma cells
Downstream effector: Down-regulation of Gli1 expression in curcumin treated-brain tumour cells
Transcriptional activity: Reduction in Gli1 mRNA level, therefore it downregulates Gli1-responsive genes
[92, 97, 98]
Notch signaling Receptor: (1) Curcumin downregulated Notch-1 at transcriptional level, which subsequently lowered the 
abundance of the receptor
(2) Curcumin suppressed Notch-1 activation through down-regulation of a key component of the 
γ-secretase protein complex in esophageal cancer cells
Transcriptional activity: Curcumin inactivated nuclear factor-kB DNA-binding activity in oral carcinoma CAL-
27 cells, thus targeting the cancer cells by activating apoptosis and reducing cell growth and invasion
[88, 89, 99]
PI3K/Akt signaling Intermediate transducer: Curcumin inhibited of the activation of PI3K/AKT/mTOR and its related pathways at 
multiple regulatory effectors via modulation of their phosphorylation status[Akt (T308 and S473), FoxO1 
(S256), GSK3β (S9), tuberin/TSC2 (T1462), mTOR (S2448/2481), p70 S6K (T389), S6 (S235/236), 4E-BP1 
(S37/46), eIF4G (S1108)]
Transcriptional activity: Curcumin decreased total expression of mTOR, Raptor and Rictor protein and mRNA 
levels
[85, 87, 93, 94]
Wnt/β-catenin signal-
ing
Receptor: Frizzled-1 (the receptor of Wnt proteins) was inhibited in curcumin- treated human head and neck 
squamous cell carcinoma cell line mda 1986
Downstream effector: Curcumin induced caspase-3-mediated cleavage of β -catenin, leading to inactivation 
of Wnt/β-catenin signaling
Transcriptional activity: Curcumin reduced β-catenin/tcf transcriptional activity via downregulation of 
β-catenin and its positive regulator, p300
[90, 91, 92, 95, 96]
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contribute to the metastatic and drug resistance proper-
ties found in CSCs [111].
Decreased expression of the miR-200 family has been rec-
ognised as one of the signatures of invasiveness and metas-
tasis progression in pancreatic cancer cells, hence indicating 
its regulatory role in tumour suppression [112]. Similarly, 
drug-resistant cancer cells which exhibited more EMT like 
properties were found to be low in the expression of miR-
200 [113, 114]. Several studies have highlighted the possible 
mechanisms by which miR-200 suppresses formation of 
CSCs, through inhibition of the self-renewal pathway evi-
denced by the downregulation of Notch-1 and BMI1, rever-
sion of EMT and regulation of a few other regulators.
The use of natural phytochemicals to manipulate the 
expression of miRNA has been proven effective in revers-
ing the EMT process in CSCs by targeting the repressor 
proteins involved and promoting cancer cell apoptosis 
[115]. For example, experimental evidence has shown the 
feasibility of reversing the EMT phenotype in pancreatic 
cancer by means of blocking the Zeb1 protein and vimen-
tin, which are highly expressed in mesenchymal cells, via 
RNAi modulation produced by in  vitro treatment with 
chemical inhibitors such as isoflavones and curcumin 
[82, 83, 106, 115]. In another recent study, curcumin was 
shown to effectively sensitize colorectal CSCs towards 
chemotherapy drugs by blocking the synergistic effect 
of HCT116 cells in the fibroblast MRC-5 cell co-culture, 
which showed an increase in EMT-phenotypic expres-
sion compared to the HCT-116 cell monoculture [80]. 
Taken together, these studies suggest the possibility of 
inhibiting CSCs by targeting EMT, and curcumin has 
been proven to be one of the effective modalities.
The results of the aforementioned studies suggest that 
individual miRNA might play multiple roles in several 
human cancers during carcinogenesis and tumour progres-
sion. Additionally, the close relationship between miRNA 
regulation and the EMT signalling process could be further 
investigated with other repressor proteins that have active 
roles in the acquisition of the EMT phenotype in malig-
nant CSCs. It can be assumed that curcumin has potential 
therapeutic properties in human cancer, mainly by target-
ing miRNA expression, and that it functions to induce cell 
apoptosis as well as to modulate drug resistance in cancer 
cells. These therapeutic properties of curcumin have been 
Fig. 3 Mechanism of action of curcumin on cancer cells and cancer stem cells via modulation of expression of miRNA. Curcumin modulated 
expression of miRNAs are clustered into different mechanism of actions which involve the reversion of CSC phenotypes and properties and there-
fore, the cells are sensitised to the anti-cancer activity of curcumin
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investigated and supported by the promising evidence from 
in vitro and preclinical studies, but the effect of curcumin 
in cancer therapy via miRNA modulation needs to be con-
firmed by more studies especially in vivo and clinical trials.
Future perspective
Curcumin and its analogues reduced colorectal can-
cer stem cell populations through various mechanisms: 
affecting signaling molecules, apoptotic genes, growth 
factor receptors, tumour spheroid formation, microR-
NAs, and epithelial-mesenchymal transition. The effects 
were seen not only in in  vitro but also in in  vivo mice 
studies as well. Curcumin reduced tumour formation 
and recurrence in chemo-resistant cancer cells by target-
ing the cancer stem cell (CSC) population. The current 
limitations for the clinical application of curcumin and 
its analogues are due to their low absorption and stability, 
thus resulting in low cellular bioavailability. Novel formu-
lations of curcumin and its analogues have been devel-
oped for better bioavailability and have been found to be 
effective in CSC inhibition. Conventional therapy, either 
chemo- or radiotherapy, specifically targets the rapidly 
dividing cells within the tumour mass. These therapies, 
however, fail to effectively eradicate the whole tumour 
Fig. 4 Schematic diagram of the outlook of advanced therapy for targeting cancer and resistant CSC incorporating nanotechnology approaches to 
improve the formulation of curcumin and its analogues to achieve better therapeutic effects. The top panel shows the typical effects of conven-
tional therapy in relation to tumour progression (middle panel), noting that CSC typically escapes the treatment, thus causing tumour recurrence 
and metastasis. The bottom panel shows the future effect of targeting the CSC population using curcumin and its analogues and the future perspec-
tive of using a nanotechnology approach to improve drug formulation
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mass, which may escape the treatment due to acquired 
chemo-resistance. This chemo-resistance is favoured by 
the tumour-stoma microniche, which plays a key role in 
EMT induction and subsequently makes the cells acquire 
CSC properties and metastasise via the blood stream to 
initiate a secondary tumour as the cancer progresses. 
Therefore, conventional therapies, even at higher doses, 
are non-effective in targeting CSC and metastasised 
cancer cells. Curcumin and its analogues, with their 
capacity to target both cancer cells and CSCs as well as 
increase the susceptibility of CSC towards chemo- and 
radiotherapy, therefore, have the potential to be devel-
oped as an adjuvant anti-cancer agent. Further investiga-
tion is underway to develop curcumin based anti-cancer 
therapy using nanotechnology approaches, such as the 
nanoparticle delivery system, to overcome the pharma-
cokinetic and pharmacodynamic drawbacks in order to 
develop an effective and targeted therapy for eradicating 
cancer (Fig. 4).
Conclusion
Overcoming tumour recurrence remains a major chal-
lenge in the treatment of colorectal cancer, due to the 
presence of the CSC population which contributes to 
chemo-resistance. Curcumin and its analogues have been 
shown to effectively kill cancer cells, and increasing evi-
dence has shown their potential in targeting CSCs via 
regulation of the signaling pathways, specific microRNAs 
and epithelial mesenchymal transition. Taken together, 
these compounds, with their promising anti-cancer and 
anti-CSC potential, can be further developed using bet-
ter formulations to enhance the efficacy of existing treat-
ment modalities.
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